P/E at 36.62 vs Industry's 35.54: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Premium Reflecting Confidence or Caution?

The current P/E of Sun Pharmaceutical Industries Ltd stands at 36.62, slightly above the Pharmaceuticals & Biotechnology industry average of 35.54. This 3.1% premium suggests that investors are willing to pay a bit more for the stock relative to its peers, potentially reflecting expectations of superior earnings growth or stability. However, the premium is not excessive, indicating a balanced valuation stance rather than exuberance. The market capitalisation of Rs 4,61,392.11 crore firmly places the company in the large-cap category, underscoring its established position within the sector.

Such a valuation premium often invites scrutiny — Sun Pharmaceutical Industries Ltd’s P/E ratio is close enough to the industry average to suggest that the market is pricing in steady performance rather than speculative upside. Sun Pharma’s valuation thus appears to be in line with sector fundamentals, but the question remains — previously rated Hold, what is Sun Pharmaceutical Industries Ltd’s current rating?

Performance Across Timeframes: Consistent Outperformance with Momentum Nuances

Examining the stock’s returns reveals a compelling story of relative strength. Over the past year, Sun Pharmaceutical Industries Ltd has delivered a 14.95% gain, comfortably outperforming the Sensex’s decline of 7.02% during the same period. This outperformance extends to shorter intervals as well, with the stock rising 12.22% over three months versus a marginal 0.35% gain for the Sensex.

Year-to-date, the stock has appreciated 11.82%, contrasting with the Sensex’s 8.67% loss. Even the one-month and one-week performances show the stock ahead of the broader market, with gains of 7.51% and 3.06% respectively. The one-day performance also reflects positive momentum, with a 1.05% increase compared to the Sensex’s 0.44% decline.

Longer-term returns further highlight the stock’s resilience. Over three years, Sun Pharma has surged 85.71%, significantly outpacing the Sensex’s 19.23%. The five-year return of 188.31% dwarfs the Sensex’s 48.06%, although the ten-year return of 147.00% trails the Sensex’s 186.92%, reflecting some cyclical variation in the company’s growth trajectory.

Despite this strong performance, the stock’s recent gains prompt the question — is this momentum sustainable or a peak before consolidation?

Moving Average Configuration: Bullish Signals Across All Key Averages

The technical picture for Sun Pharmaceutical Industries Ltd is notably positive. The stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, signalling a strong upward trend across both short and long-term horizons. This configuration typically indicates sustained buying interest and a robust recovery or continuation of an uptrend.

Being above all these key moving averages suggests that the stock has overcome recent resistance levels and is in a technically healthy position. This is particularly significant given the sector’s mixed results, where only a subset of companies have managed to maintain such consistent momentum. The question arises — is this a genuine recovery or a relief rally that will fade at the 50 DMA? — the moving average configuration provides the clearest answer.

Sector Context: Pharmaceuticals & Biotechnology Showing Mixed but Positive Trends

The Pharmaceuticals & Biotechnology sector, to which Sun Pharmaceutical Industries Ltd belongs, has exhibited a generally positive performance trend recently. While some companies in the sector have faced headwinds due to regulatory challenges and pricing pressures, the overall sector has recorded more positive results than negative ones in the latest quarterly cycle.

This sector backdrop supports the valuation premium observed in Sun Pharma, as investors appear to favour companies with strong fundamentals and resilient earnings growth. However, sector volatility remains a factor, and the stock’s outperformance relative to peers invites scrutiny — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Rating Context: Previously Rated Hold, Now Reassessed

On 8 June 2026, the rating for Sun Pharmaceutical Industries Ltd was updated from a previous Hold rating assigned by MarketsMOJO. The reassessment reflects the company’s improved performance metrics, valuation alignment, and technical strength. The Mojo Score of 74.0 supports a positive view, although the current rating itself is not disclosed.

This rating update coincides with the stock trading near its 52-week high, just 1.16% shy of the peak price of Rs 1925. The stock’s ability to sustain gains above all major moving averages further validates the reassessment. The question remains — what is the current rating for Sun Pharmaceutical Industries Ltd?

Conclusion: Data Reflects Balanced Valuation and Strong Momentum

The comprehensive data analysis for Sun Pharmaceutical Industries Ltd reveals a stock trading at a slight premium to its sector, supported by consistent outperformance across multiple timeframes. The technical indicators, with the stock positioned above all key moving averages, reinforce a bullish momentum narrative. Sector performance is broadly positive, lending further context to the company’s valuation and rating reassessment.

While the stock’s one-year and medium-term returns have been robust, the proximity to its 52-week high and the premium valuation invite careful consideration — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →